Life Science Investing Stoke Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Life Science Investing Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society Annual Meeting
Life Science Investing Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Life Science Investing Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting
Life Science Investing Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Life Science Investing Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
Life Science Investing Stoke Therapeutics to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference
Life Science Investing Stoke Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Life Science Investing Stoke Therapeutics to Host Webcast and Conference Call to Discuss Third Quarter 2025 Business and Financial Updates
Life Science Investing Stoke Therapeutics Presents Two-Year Natural History Data from Patients with Autosomal Dominant Optic Atrophy
Life Science Investing Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Life Science Investing Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
Life Science Investing Biogen and Stoke Therapeutics Present Data at the 36th International Epilepsy Congress that Support the Potential for Zorevunersen to be the First Disease-Modifying Medicine for Dravet Syndrome
